8-K: VSee Health Designates Series B Convertible Preferred Stock

VSee Health, Inc. has designated up to 2,000 shares of Series B Convertible Preferred Stock with a $1,000 stated value, establishing new terms for capital structure.

Summary

• VSee Health, Inc. filed a Certificate of Designation for Series B Convertible Preferred Stock, effective December 5, 2025.
• Up to 2,000 shares of Series B Preferred Stock are designated, each with a par value of $0.0001 and a stated value of $1,000.
• The Series B Preferred Stock ranks senior to common stock and junior securities, on parity with Series A Preferred Stock, and junior to any future senior securities regarding dividends and liquidation.
• Holders are entitled to dividends equal to common stock dividends on an as-if-converted basis, with no other dividends paid.
• Voting rights are limited to what is required by Delaware law, but a majority vote of Series B holders is required for changes affecting their rights.
• Upon liquidation, holders receive the $1,000 stated value per share plus accrued unpaid dividends, prior to common stock, and then participate pari passu with common stock as if fully converted.
• Shares are convertible into common stock at the holder's option if Investor Gross Proceeds from the sale of Investor Shares are less than $2.3 million.
• The conversion price is $0.65 per share of common stock.
• A beneficial ownership limitation prevents conversion if it would result in a holder (with affiliates) owning more than 9.99% of the outstanding common stock.
• Any outstanding Series B Preferred Stock or conversion shares will be automatically cancelled if Investor Gross Proceeds equal or exceed $2.132 million.
• The Investor, Manatt, Phelps & Phillips, LLP, was issued 3,000,000 shares of Common Stock further to a Purchase Agreement dated November 21, 2025.

Sentiment

Score: 6

Explanation: The designation of Series B Convertible Preferred Stock provides a structured way to raise capital or manage existing financing arrangements. While it offers flexibility and potential for funding, the senior ranking and conversion terms could lead to dilution for common shareholders, introducing some uncertainty. The specific details of the underlying Purchase Agreement and the Investor's role are crucial for a full assessment, but the filing itself is a neutral corporate action with both potential benefits and drawbacks.

Positives

• The creation of Series B Preferred Stock provides a flexible mechanism for capital raising or restructuring.
• The preferred stock structure offers enhanced liquidation preference and dividend rights (on an as-if-converted basis) compared to common stock, potentially attracting specific types of investors.

Negatives

• The Series B Preferred Stock ranks senior to common stock in liquidation, potentially diluting common shareholders' recovery in a dissolution event.
• The conversion price of $0.65, if significantly below the current market price of common stock, could lead to substantial dilution for existing common shareholders upon conversion.
• The beneficial ownership limitation of 9.99% restricts a single holder's ability to convert a large block of preferred shares into common stock, which could impact liquidity or control.
• The automatic cancellation clause tied to 'Investor Gross Proceeds' and 'Investor Amount' suggests a specific financing arrangement that might be complex or tied to performance metrics of the Investor's sale of common shares, which is not fully detailed in the 8-K itself.

Risks

• Dilution Risk: Conversion of Series B Preferred Stock into common stock at $0.65 per share could dilute the ownership percentage and earnings per share for existing common shareholders, especially if the market price is higher.
• Liquidation Preference Risk: In the event of liquidation, Series B Preferred Stockholders receive their stated value and accrued dividends before common stockholders, increasing risk for common equity.
• Voting Power Limitations: Common shareholders' voting power could be indirectly affected by the existence of preferred stock, even if the preferred stock has limited direct voting rights, as certain corporate actions require preferred shareholder consent.
• Market Perception: The issuance of preferred stock, especially convertible preferred stock, can sometimes be perceived by the market as a sign of financial distress or difficulty in raising capital through common equity.
• Complexity of Capital Structure: The introduction of a new class of preferred stock adds complexity to the company's capital structure, which can be harder for investors to analyze.

Future Outlook

The filing outlines the terms for a new class of preferred stock, which could be used for future capital raising or as part of a broader financing strategy. The conversion mechanism tied to "Investor Gross Proceeds" suggests an expectation of future sales of common shares by the Investor.

Management Comments

• The Board of Directors does hereby provide for the issuance of a series of preferred stock for cash or exchange of other securities, rights or property and does hereby fix and determine the rights, preferences, restrictions and other matters relating to such series of preferred stock.

Industry Context

The designation of convertible preferred stock is a common financing tool used by companies, particularly those in growth phases or seeking to optimize their capital structure. It allows companies to raise capital with terms that can be more attractive to certain investors than common equity, often providing a balance between debt and equity characteristics. For a health technology company like VSee Health, this could be a way to fund ongoing development, expansion, or strategic initiatives without immediately diluting common shareholders as much as a direct common stock offering might.

Comparison to Industry Standards

• The use of convertible preferred stock is a standard financing instrument, particularly for smaller or growth-stage companies that may find it challenging to raise pure equity or debt on favorable terms.
• The 9.99% beneficial ownership limitation is a common provision in convertible securities to prevent a single investor from triggering reporting requirements under Section 13D of the Exchange Act, which applies to beneficial ownership exceeding 10%. This is a standard practice to manage regulatory burdens for investors.
• The liquidation preference and dividend structure are typical for preferred stock, offering a layer of protection and income priority over common equity, which is standard for this class of security.

Corporate Governance

Related Party Transactions

• Manatt, Phelps & Phillips, LLP is identified as the "Investor" in a Securities Purchase Agreement dated November 21, 2025, and was issued 3,000,000 shares of Common Stock. This transaction is linked to the terms of the Series B Preferred Stock.

Stakeholder Impact

• Shareholders (Common Stock): Potential for dilution upon conversion of Series B Preferred Stock at $0.65 per share. Common stock ranks junior to Series B Preferred Stock in liquidation.
• Shareholders (Series B Preferred Stock): Receive liquidation preference and specific dividend rights. Have conversion options under certain conditions.
• Creditors: Series B Preferred Stock ranks junior to existing and future creditors, meaning creditors would be paid before preferred stockholders in a liquidation scenario.

Next Steps

• The company will proceed with the terms outlined in the Series B Certificate of Designations, including potential issuance and conversion of the preferred stock.
• Holders of Series B Preferred Stock may convert their shares into common stock if the "Investor Gross Proceeds from the sale of all Investor Shares is less than $2.3 million."
• Outstanding Series B Preferred Stock or Conversion Shares will be automatically cancelled if "Investor Gross Proceeds equals or exceeds the Investor Amount" ($2.132 million).

Key Dates

Recommendation

The filing details a corporate action to designate Series B Convertible Preferred Stock, which is a financing mechanism. While it provides a framework for potential capital infusion, the immediate impact on the company's operational performance or financial health is not detailed. The conversion price of $0.65 could lead to dilution for common shareholders if the market price is higher, but the overall effect depends on the specific terms of the underlying Purchase Agreement and the company's future performance. Without more information on the company's current valuation, financial results, and the strategic rationale behind this specific financing structure, a "hold" recommendation is prudent, advising investors to await further clarity on the use of proceeds and the broader financial implications before making a definitive buy or sell decision.

Keywords

VSee Health, Series B Preferred Stock, Convertible Preferred Stock, SEC Filing, 8-K, Corporate Governance, Capital Structure, Stock Designation, Preferred Shares, Common Stock Conversion, Dilution, Liquidation Preference, Manatt Phelps & Phillips